[et_pb_section fb_built=”1″ _builder_version=”4.7.0″ _module_preset=”default”][et_pb_row column_structure=”1_3,2_3″ _builder_version=”4.7.0″ _module_preset=”default”][et_pb_column type=”1_3″ _builder_version=”4.7.0″ _module_preset=”default”][et_pb_image src=”http://www.rest-therapeutics.com/wp-content/uploads/2020/11/AD-PD-illustr.jpg” title_text=”AD-PD-illustr” url=”https://adpd.kenes.com/” url_new_window=”on” _builder_version=”4.7.4″ _module_preset=”default” box_shadow_style=”preset1″][/et_pb_image][/et_pb_column][et_pb_column type=”2_3″ _builder_version=”4.7.0″ _module_preset=”default”][et_pb_text content_last_edited=”off|desktop” _builder_version=”4.7.4″ _module_preset=”default” text_font_size=”16px” background_color=”#ffffff”]

Dr. Tangui Maurice of Montpellier University and ReST’s scientific partner will present FENM results on Alzheimer during the upcoming 15th International Conference on Alzheimer’s and Parkinson’s Diseases: Mechanisms, Clinical Strategies and promising Treatments of Neurodegenerative Diseases.

The Virtual Conference will take place March 9-14, 2021.

Access the full program here.

 

The oral presentation will demonstrate that  FENM appeares as a potent neuroprotective drug in an AD model, with a superior efficacy compared with Memantine and an absence of direct amnesic effect at higher doses, which open the possibility to use the compound at more relevant dosages than those actually proposed in Memantine treatment for AD.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]